옵션 체인은 다양한 행사가격과 만기일에 대한 Traws Pharma의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Traws Pharma에 대한 시장 심리를 평가합니다..

Traws Pharma (NASDAQ:TRAW) 주식, 옵션 체인

Traws Pharma

Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.

Traws Pharma Inc

TraWell Co SpA

Brazilian authorities said on Monday that they have halted the construction of the plant that Chinese EV giant BYD Co Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) is building in Salvador, Bahia after finding workers living and working in conditions analogous to &#8220;slavery.&#8221;
What Happened: Authorities ordered that the construction of the factory in Bahia be stopped after rescuing 163 people working at the site, according to a statement by the Labor Prosecutor&#8217;s Office (MPT).
The authorities shut down the workers&#8217; lodgings and communicated the same to both BYD and construction firm Jinjiang Construction Brazil Ltd, one of the contractors hired by the company to carry out the construction, it added.
MPT&#8217;s statement said that the workers lived in conditions analogous to slavery across four main lodgings. In one of the lodgings, the workers slept on beds without mattresses and 31 workers shared one bathroom, it said. 
At the construction site, there were only eight badly maintained chemical toilets for about 600 workers, it said, while also noting multiple accidents at the site. In one case, a worker suffered an accident after not having a break for 25 days.
The MPT also noted that the conditions constituted &#8220;forced labor.&#8221; If a worker were to terminate their employment contract after six months, they would leave the country without any pay for their work since the company deducted their airfare to and from Brazil, in addition to other costs, the statement said. 
BYD did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga&#8217;s</a> request for comment.
Why It Matters: BYD is China&#8217;s largest EV maker and makes plug-in hybrids and battery electric vehicles which are sold in China, Europe, and also Brazil. In November alone, the company made 540,588 new energy vehicles as compared to 316,510 in the corresponding month of 2023.
BYD <a href="https://www.benzinga.com/news/24/01/36839203/warren-buffett-backed-byd-sees-higher-profits-for-fy23-after-taking-over-tesla-as-biggest-ev-seller" target="_blank" rel="noreferrer noopener">took over Tesla</a>&nbsp;as the world's largest BEV seller in the fourth quarter of 2023. However, Tesla took back the crown in the first quarter of 2024 and has been holding on to it since.
For the third quarter between July and September, BYD reported operating revenue of&nbsp;<a href="https://www.benzinga.com/news/24/10/41647639/teslas-chinese-rival-byd-outshines-elon-musks-ev-giant-in-quarterly-revenue-for-first-time-since-202" target="_blank" rel="noreferrer noopener">201.12 billion yuan ($28.25 billion)</a> and net profit of 11.6 billion yuan. 
The company&#8217;s new factory in Bahia was expected to be operational by next year.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42666472/gms-60000-cadillac-lyriq-was-its-best-selling-ev-in-2024-as-of-q3-is-premium-the-way-to-go-for-ev-makers" target="_blank" rel="noreferrer noopener">GM's $60,000 Cadillac Lyriq Was Its Best Selling EV In 2024 As Of Q3: Is Premium The Way To Go For EV Makers?</a></li>
</ul>
Photo courtesy: Shutterstock

Government

News

Global

Tech

BYDDY

Brazil Authorities Halt Work At BYD Factory Site After Workers Found In 'Slavery' Like Conditions

Allurion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company's common stock, par value $0.0001 per share (the "Common Stock").
The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 3, 2025, and the Company's Common Stock will begin trading on a split-adjusted basis on The New York Stock Exchange ("NYSE") as of the opening of trading on January 3, 2025. The CUSIP number of 02008G 201 will be assigned to the Company's Common Stock when the reverse stock split becomes effective.
When the reverse stock split becomes effective, every twenty five (25) of the Company's issued shares of Common Stock will be combined into one (1) issued share of Common Stock, without any change to the par value per share. This will reduce the number of outstanding shares of Common Stock from approximately 67,781,585 million shares to approximately 2,711,263 million shares.

Stock Split

ALUR

Allurion Technologies Announces 1-for-25 Reverse Stock Split Effective January 3

D. Boral Capital analyst Jason Kolbert initiates coverage on AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) with a Buy rating and announces Price Target of $25.

Price Target

Initiation

Analyst Ratings

RCEL

D. Boral Capital Initiates Coverage On AVITA Medical with Buy Rating, Announces Price Target of $25

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54170813&amp;newsitemid=20241224565771&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=c412227958438d701e3e355f86717b04">Enanta Pharmaceuticals, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts ("the Court") has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 ("the '953 Patent") in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid&#x2122; (nirmatrelvir tablets; ritonavir tablets).
The Court issued a summary judgment decision granting Pfizer's motion that the ‘953 Patent is invalid. In its decision, the Court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit.

Regulations

Legal

ENTA

Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned

Webuy Global Ltd (NASDAQ:<a href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) (the "Company") is pleased to announce the remarkable success of its recent Disney cruise campaign, powered by its revolutionary Micky1.0 Travel AI on WhatsApp. By seamlessly integrating advanced AI technology with personalized customer service, Webuy demonstrated its ability to drive significant customer engagement and financial results.
 AI-Driven Success &nbsp;
The Disney cruise campaign leveraged Webuy's digital marketing expertise to direct leads to Micky1.0, the Company's AI-powered travel assistant. Micky1.0 efficiently answered customer inquiries, provided real-time quotes, and tailored recommendations, before transferring qualified leads to travel consultants for deal closure. This streamlined process highlights the synergy between advanced technology and human expertise.
 Outstanding Results &nbsp;
From December 10th to 23rd,2024,&nbsp; the Disney campaign exclusively drove the following financial achievements: • &nbsp; &nbsp;Receivable Booking Value (RBV): SGD 465,527 • &nbsp; &nbsp;Booking Revenue: SGD 162,202 These figures highlight the significant impact of the Disney project, powered by Webuy's AI capabilities, on revenue growth. &nbsp;

WBUY

Webuy Global Achieves Revenue Milestone With AI-Driven Disney Cruise Campaign

Ratings for Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.21, a high estimate of $26.00, and a low estimate of $14.50. This current average has increased by 4.32% from the previous average price target of $21.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1735041643_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Nordstrom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$24.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$14.50</td>
<td>$13.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nordstrom. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Nordstrom compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Nordstrom's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Nordstrom's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JWN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nordstrom analyst ratings.</a>
<h2>Delving into Nordstrom's Background</h2>
Nordstrom is a fashion retailer that operates about 93 department stores and 280 off-price Nordstrom Rack stores. The company also operates both full- and off-price e-commerce sites, two clearance stores, and six Local locations. Nordstrom's largest merchandise categories are women's apparel (27% of 2023 sales), shoes (26% of 2023 sales), men's apparel (15% of 2023 sales), and beauty (13% of 2023 sales). Nordstrom, which traces its history to a shoe store opened in Seattle in 1901, continues to be partially owned and managed by members of the eponymous family.
<h3>Nordstrom's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Nordstrom's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 4.34%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Nordstrom's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 1.33%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Nordstrom's ROE stands out, surpassing industry averages. With an impressive ROE of 4.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Nordstrom's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.51%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Nordstrom's debt-to-equity ratio surpasses industry norms, standing at 4.37. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Have This To Say About Nordstrom

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.67, a high estimate of $27.00, and a low estimate of $18.00. This current average has decreased by 10.93% from the previous average price target of $24.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1735041636_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Enanta Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Enanta Pharma. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Enanta Pharma compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Enanta Pharma's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Enanta Pharma's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ENTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enanta Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Enanta Pharma Better</h2>
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
<h3>Financial Insights: Enanta Pharma</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Enanta Pharma faced challenges, resulting in a decline of approximately -22.84% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Enanta Pharma's net margin excels beyond industry benchmarks, reaching -197.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Enanta Pharma's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -20.76%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Enanta Pharma's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.43%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.43, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Throughout the last three months, 4 analysts have evaluated Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Glimpse Group, revealing an average target of $3.66, a high estimate of $4.67, and a low estimate of $2.65. This upward trend is apparent, with the current average reflecting a 16.19% increase from the previous average price target of $3.15.
<img src="https://www.benzinga.com/files/images/story/2024/1735041629_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Glimpse Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.67</td>
<td>$4.67</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>Westlake Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.67</td>
<td>$2.65</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.65</td>
<td>$2.65</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.65</td>
<td>$2.65</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Glimpse Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Glimpse Group compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Glimpse Group's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VRAR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glimpse Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Glimpse Group Better</h2>
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
<h3>Unraveling the Financial Story of Glimpse Group</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Glimpse Group's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -21.47%. This indicates a decrease in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Glimpse Group's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -41.59%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Glimpse Group's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -9.04%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.6%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Glimpse Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRAR

Glimpse Group Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

FlexShopper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $2.88, along with a high estimate of $4.00 and a low estimate of $2.50. Observing a 21.01% increase, the current average has risen from the previous average price target of $2.38. 
<img src="https://www.benzinga.com/files/images/story/2024/1735041620_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive FlexShopper is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Michael Diana</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to FlexShopper. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of FlexShopper compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of FlexShopper's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into FlexShopper's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FPAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on FlexShopper analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About FlexShopper</h2>
FlexShopper Inc is a financial technology company engaged in providing certain types of durable goods to consumers on a lease-to-own basis and providing lease-to-own (LTO) terms to consumers of third-party retailers and e-tailers. Its products include electronics, computers, furniture, mattresses, cameras and camcorders, audio, musical instruments, health, fitness and sports, video games, homes, gardens and tools, appliances, and vacuums on a payment, lease basis. The firm generates a majority of its revenue by leasing its products. The company enables consumers utilizing its e-commerce marketplace to shop for brand-name electronics, home furnishings, and other durable goods on a lease-to-own (LTO) basis.
<h3>Breaking Down FlexShopper's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining FlexShopper's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 22.95% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.08%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 20.37%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): FlexShopper's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.66%, the company showcases efficient use of assets and strong financial health.
Debt Management: FlexShopper's debt-to-equity ratio is notably higher than the industry average. With a ratio of 21.36, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FPAY

The Analyst Verdict: FlexShopper In The Eyes Of 4 Experts

Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD).
The trial will be led at Yale School of Medicine's Department of Psychiatry by Dr. Anahita Bassir Nia, MD, an expert in psychiatry and addiction medicine. This milestone marks a significant step forward in Clearmind's FDA-regulated clinical program, further expanding the multi-site trial to evaluate the safety, tolerability and efficacy of its proprietary investigational drug, CMND-100.

CMND

Clearmind Medicine Secures IRB Approval For Alcohol Use Disorder Trial At Yale

On Monday, Olympian Motors announced an <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42664434/olympian-motors-and-nvidia-pioneer-the-first-ai-powered-ev-platforms" rel="noreferrer noopener">expanded collaboration with</a> Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to develop the&nbsp;Olympus Platform, an open, modular, artificial intelligence-powered electric vehicle (EV) platform.
The strategic partnership leverages Nvidia&#8217;s advanced computing solutions, including the DRIVE AGX Orin platform and the Nvidia Inception Program, to create a new protocol for designing and deploying AI models to EVs.
The Olympus EV Platform launches a modular approach to EV hardware and software architecture.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42659936/meta-plans-display-equipped-ray-ban-glasses-by-2025-aiming-to-replace-smartphones" rel="noreferrer noopener">Meta Plans Display-Equipped Ray-Ban Glasses By 2025: FT</a>
Developers can easily access the open, modular vehicle OS and cloud and deploy machine learning models and applications.
The Olympus Platform targets the launch of real-time physical sensing and simulation systems, crash-test simulations and real-time safety analysis, predictive safety protocols, modular vehicle configurations for rapid manufacturing and supply chain, and configurable AI-driven cockpit systems.
Last week, the companies <a target="_blank" href="https://www.benzinga.com/content/42503019/olympian-motors-and-nvidia-collaborate-to-deliver-the-first-open-modular-ev-platform" rel="noreferrer noopener">announced their partnership</a> to develop advanced electric vehicles powered by Nvidia&#8217;s DRIVE AGX Orin platform.
Nvidia stock surged 190% year-to-date, backed by the AI frenzy.
Wedbush&#8217;s Dan Ives expects the <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41151741/nvidias-ai-leadership-to-drive-1-trillion-market-growth-with-accenture-partnership-" rel="noreferrer noopener">upcoming $1 trillion</a> in AI capital investment from Big Techs and startups to significantly boost Nvidia&#8217;s position. He noted that every $1 paid on an Nvidia GPU translates into a $8-$10 multiplier across the tech sector.
Investors can gain exposure to Nvidia through VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and Fidelity MSCI Information Technology Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTEC#NYSE">FTEC</a>).
Price Action: NVDA stock traded lower by 0.20% to $139.40 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42657620/amd-and-micron-top-analyst-picks-for-ai-and-next-gen-tech-growth" target="_blank" rel="noreferrer noopener">AMD and Micron Are Top Analyst Picks for AI and Next-Gen Tech Growth</a></li>
</ul>
Photo via Company

BABA

FTEC

NVDA

XIACF

XIACY

Nvidia's Advanced AI Tech Powers Olympian Motors' New Electric Vehicle Platform

Crypto derivatives exchange Deribit is building on the success of its recent addition, Pax Gold, as it explores expanding into <a href="https://www.benzinga.com/news/events/24/11/42012198/a-new-era-how-tokenization-could-reduce-frictions-and-potentially-costs-in-finance">asset-backed crypto products</a>.
Within its first week, PAXG trading on Deribit exceeded $250 million in notional value, signaling strong interest in gold-backed tokens among traders, according to company executives. 
In an interview with Benzinga, Shaun Fernando, Chief Risk Officer and Head of Product Strategy at Deribit, described the debut as aligned with market demand. 
"There's significant overlap between gold and crypto traders," he said, adding, "PAXG provides stability and flexibility, making it a natural fit for our platform."
PAXG, backed 1:1 by LBMA-accredited gold reserves, offers traders several advantages, including 24/7 trading, no management fees, and reduced transaction costs compared to traditional gold ETFs, he said.
Fernando highlighted PAXG's role in addressing inflation risks and its potential as a stable collateral asset. "It's a much more stable asset," he noted. "You can use it as a cross-collateral coin while hedging your inflation risk."
The success of PAXG has also prompted Deribit to consider other high-value asset-backed products. 
CEO Luuk Strijers emphasized the company's focus on quality in product expansion. 
"We focus on quality, not quantity," Strijers said. "Our goal is to provide long-term value by identifying assets with real demand and stability."
Strijers also pointed to PAXG's utility within Deribit's ecosystem, particularly its role as cross-collateral. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42655154/84000-is-bitcoins-worst-case-options-trading-firm-ceo-says">$84,000 Is Bitcoin&#8217;s Worst Case, Options Trading Firm CEO Says</a>
"Traders can use gold to hedge risk while maintaining liquidity for other strategies, something not possible with traditional gold products," he explained. 
This functionality allows traders to diversify their portfolios and manage market risks more effectively.
Fernando pointed out that gold's unique characteristics as a stable asset make it particularly appealing to traders seeking diversification. 
"Gold has moved 27% year to date, showing significant activity driven by factors like Federal Reserve actions and geopolitical tensions," Fernando said. 
Strijers added that the decision to prioritize gold-backed tokens was based on their proven demand and utility. 
"We are not just adding products for the sake of it. PAXG fits well with our focus on high-quality assets that provide long-term value," he said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42652101/microstrategy-adds-5262-bitcoin-to-bring-holdings-to-over-444000-btc">MicroStrategy Adds 5,262 Bitcoin To Bring Holdings To Over 444,000 BTC</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Deribit Eyes Growth In Asset-Backed Crypto With Pax Gold Debut

On Monday, December 23rd, U.S. markets closed higher, with the Nasdaq and Dow marking three straight gains, driven by strong performances from tech giants like Meta, Nvidia, and Tesla. Lighter holiday trading volumes amplified moves as investors adjusted to the Federal Reserve&#8217;s signals of a slower pace of rate cuts.
In economic data, the Chicago Fed National Activity Index improved to -0.12 in November from -0.5 in October. U.S. durable goods orders fell 1.1% to $285.1 billion, missing market expectations of a 0.4% decline.
Most S&amp;P 500 sectors rose, led by communication services, health care, and tech, while consumer staples and materials lagged and closed lower.
The Dow Jones Industrial Average was up 0.16% and closed at 42,906.95, the S&amp;P 500 closed higher by 0.73% at 5,974.07, and the Nasdaq Composite gained 0.98% to finish at 19,764.88.
Asia Markets Today
<ul>
<li>On Tuesday, Japan&#8217;s Nikkei 225 declined 0.26% and ended the session at 39,071.50, led by losses in the Railway &amp; Bus, Transport and Fishery sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 rose 0.24% and ended the day at 8,220.90, led by gains in the A-REITs, Healthcare, and Energy sectors.</li>
<li>India&#8217;s Nifty 50 slid 0.10% to 23,729.25, and the Nifty 500 was down 0.08%, closing at 22,393.50. Losses in the fast-moving consumer goods, metals, and healthcare sectors led to the decline.</li>
<li>China&#8217;s Shanghai Composite rose 1.26% to close at 3,393.53, and the Shenzhen CSI 300 gained 1.27%, finishing the day at 3,983.69.</li>
<li>Hong Kong&#8217;s Hang Seng was up 1.08% and closed the session at 20,121.91.</li>
</ul>
Eurozone at 06:00 AM ET
<ul>
<li>The European STOXX 50 index was down 0.22%.</li>
<li>Germany&#8217;s DAX slid 0.18%.</li>
<li>France&#8217;s CAC gained 0.56%.</li>
<li>U.K.&#8217;s FTSE 100 index traded higher by 0.51%.</li>
</ul>
Commodities at 06:00 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.92% at $69.88/bbl, and Brent was up 0.86% at $72.94/bbl.</li>
<li>Oil prices rose, supported by a positive short-term market outlook, signs of higher demand, and China&#8217;s fiscal stimulus plans.</li>
<li>Natural Gas rose 2.99% to $3.447.</li>
<li>Gold was trading higher by 0.08% at $2,630.40, Silver was up 0.01% to $30.192 and rose 0.83% to $4.1185.</li>
</ul>
U.S. Futures at 06:00 AM ET
Dow futures were up 0.01%, S&amp;P 500 futures were up 0.10%, and Nasdaq 100 futures gained 0.15%.
Forex at 06:00 AM ET
The U.S. Dollar Index was up 0.14% to 108.18, USD/JPY slid 0.04% to 157.09, and USD/AUD rose 0.25% to 1.6042.
Photo by Steve Heap on Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Mixed, Dollar Holds Strong - Global Markets Today While US Slept

HC Wainwright &amp; Co. analyst Ed Arce reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Buy and maintains $95 price target.

Reiteration

RARE

HC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $95 Price Target

U.S. stock futures advanced on Tuesday, ahead of a shortened trading session owning to Christmas Eve. The stock market will shut at 1 p.m. ET, while the bond market closes at 2:00 p.m. ET on Tuesday, whereas both the markets will remain closed for Christmas on Dec. 25. Futures of all four major indices advanced.
The S&amp;P 500 index is on its way to registering a robust 20% plus return for the second consecutive year in 2024, as most analysts expect a &#8220;Santa Rally&#8221; during this time of the year.
The 10-year and two-year Treasury notes yielded 4.59% and 4.34%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025 decision was at 91.4%, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.19%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.12%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.02%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Tuesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.16% to $595.67 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.24% to $524.10, according to <a href="https://pro.benzinga.com/dashboard">Benzinga</a> Pro data.
Cues From The Last Session
U.S. stocks rebounded on <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42666701/nasdaq-gains-around-1-as-tesla-nvidia-rise-ahead-of-christmas-greed-index-remains-in-fear-zone">Monday</a>, with the tech-heavy Nasdaq leading the gains. The Nasdaq Composite surged 0.98%, buoyed by strong performances from Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Economic data released on Monday showed mixed results. The Chicago Fed National Activity Index improved slightly, while U.S. durable goods orders unexpectedly declined.
Sector performance was varied. Communication services, healthcare, and information technology led the gains, while consumer staples and materials lagged. Last week, all major indices posted losses. The Dow Jones Industrial Average suffered its third consecutive losing week, declining by roughly 2.3%. The S&amp;P 500 and Nasdaq Composite also experienced declines, falling by approximately 2% and 1.8%, respectively. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.98%</td>
<td>19,764.89</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.73%</td>
<td>5,974.07</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.16%</td>
<td>42,906.95</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.22%</td>
<td>2,237.44</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
According to the chief market strategist at Carson Research, Ryan Detrick even though the last seven days of the previous year were negative, &#8220;The next 7 days are officially the Santa Claus Rally period.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The next 7 days are officially the Santa Claus Rally period. Down last year, but down back-to-back years only twice since 1950. <a href="https://t.co/S5czvrd6SY">pic.twitter.com/S5czvrd6SY</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1871296502536307092?ref_src=twsrc%5Etfw">December 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Detrick also added that no other seven-day period except the last seven days of the year is more likely to be higher. This period of &#8220;Santa Rally&#8221; has given positive returns at least 78.4% of the time.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">These next 7 trading days are known as the Santa Claus Rally period. There is no 7 day period more likely to be higher (78.4% of the time) and only two 7 day periods have a better avg return (1.29%). &#x1f385; <a href="https://t.co/40qVwHa1rS">pic.twitter.com/40qVwHa1rS</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1871322312219468049?ref_src=twsrc%5Etfw">December 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He also added that this year has seen only an 8.5% correction or peak-to-through pullback in August, however, on average a year sees a 14.2% correction, increasing the possibility of some correction in 2025.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">S&amp;P 500 up about 25% this year with only an 8.5% peak-to-through pullback all year (August). Just remember the avg year sees an 14.2% correction, which increases the odds it might happen next year. <a href="https://t.co/nV9i2yL9dU">pic.twitter.com/nV9i2yL9dU</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1871299031672205315?ref_src=twsrc%5Etfw">December 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
While the <a href="https://x.com/RyanDetrick/status/1871317802306707882">first</a> year of a new president&#8217;s term has usually been strong since 1897, the returns during the first year of a second term haven&#8217;t been very good overall, Detrick said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Returns during year one of a second term haven&#39;t been very good overall, but way better lately. Down 5 in a row, but now up 4 in a row. &#x1f914; <a href="https://t.co/aUrCbf22Gw">pic.twitter.com/aUrCbf22Gw</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1871320275129967103?ref_src=twsrc%5Etfw">December 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Talking about the proposed policy changes by President-elect Donald Trump, Louis Navellier of Navellier &amp; Associates said, &#8220;On the table is all the uncertainty about the many changes that the new Trump administration has announced, both how quickly they will be implemented and what the ripple effects might be especially tariffs. The conflicts in the Mideast and Ukraine appear to be escalating. In the end, these many risks will only impact stocks if they impact earnings, and for now, estimates for &#8217;25 are holding.
&#8220;Optimistic analyst targets, stretched positioning and high valuations leave the market vulnerable to larger pullbacks in our view, should we see any of the rosy projections falling short of lofty expectations. This does not leave us underweight Equities. We acknowledge the power of bull markets mean there may still be room to run,&#8221; said Mario Georgiou, executive director, head of investments, at InCred Global Wealth.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
A few important data points are slated to be released in this truncated week that will help investors determine the future course of action.
<ul>
<li>On Tuesday, November&#8217;s data for durable goods orders and durable goods minus transportation will be released at 8:30 a.m., ET.</li>
<li>New home sales for November will be released at 10:00 a.m. ET.</li>
<li>On Thursday, initial jobless claims data till Dec. 21 will announced at 8:30 a.m. ET.</li>
<li>On Friday, November&#8217;s data for the advanced U.S. trade balance in goods, advanced retail inventories, and advanced wholesale inventories will be announced at 8:30 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Carbon Revolution PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) was up 56.81% in premarket after it inked an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.</li>
<li>Avinger Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) was up 236.4%. Last week, the company announced it has received a Notice of Allowance for a U.S. patent titled "Catheter Device With Detachable Distal End (For The Treatment Of Peripheral Artery Disease)."</li>
<li>Tivic Health Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) was up 68% after the company&#8217;s CEO outlined 2025 priorities, seeing a 30% reduction in net operating loss.</li>
<li>Neuehealth Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) gained 58.93% after it entered into a definitive merger to be acquired for $7.33 per share.</li>
<li>Theriva Biologics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NYSE">TOVX</a>) rose 30% after it received a notice of allowance for a U.S. Patent titled "Microbiome Protection from Oral Antibiotics."</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were higher in the early New York session by 0.77% to hover around $69.77 per barrel.
The gold spot index was up by 0.11% to $2,631.19 per ounce. The Dollar Index was up 0.16% to 108.210 level.
Asian markets were mixed on Tuesday, as Hong Kong&#8217;s Hang Seng, China&#8217;s CSI 300 and Australia&#8217;s ASX 200 index rose. Whereas, South Korea&#8217;s Kospi, Japan&#8217;s Nikkei 225, and India&#8217;s S&amp;P BSE Sensex index declined. Most European markets traded higher.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42640560/japan-cannot-happen-here-was-common-refrain-20-years-ago-in-the-west-mohammed-el-erian-says-as-tokyo-climbs-out-of-the-hole-this-country-looks-at-risk-of-falling-in">Mohammed El Erian Says This Country Faces Japan-Style Economic Risk Even As Tokyo Rebounds</a></li>
</ul>
Photo courtesy: Wikimedia

Equities

Economics

Federal Reserve

Pre-Market Outlook

Markets

Trading Ideas

ETFs

AVGR

CREV

NEUE

TIVC

TOVX

TSLA

US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst

HC Wainwright &amp; Co. analyst Ed Arce maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Buy and lowers the price target from $27 to $18.

HC Wainwright & Co. Maintains Buy on Enanta Pharma, Lowers Price Target to $18

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) with a Neutral and maintains $5 price target.

ZURA

HC Wainwright & Co. Reiterates Neutral on Zura Bio, Maintains $5 Price Target

<a href="https://www.reuters.com/world/china/china-plans-411-bln-special-treasury-bond-issuance-next-year-sources-say-2024-12-24/" title="https://www.reuters.com/world/china/china-plans-411-bln-special-treasury-bond-issuance-next-year-sources-say-2024-12-24/">https://www.reuters.com/world/china/china-plans-411-bln-special-treasury-bond-issuance-next-year-sources-say-2024-12-24/</a>

Macro Economic Events

Bonds

Reuters Reported Earlier, China Plans $411B Special Treasury Bond Issuance Next Year

HC Wainwright &amp; Co. analyst Scott Buck reiterates FlexShopper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) with a Buy and maintains $2.5 price target.

HC Wainwright & Co. Reiterates Buy on FlexShopper, Maintains $2.5 Price Target

Reuters Reported Late Monday, China's National Fiscal Work Conference Said Will Step Up Fiscal Spending, Accelerate Spending Speed In 2025; Will Focus More On People's Livelihood, Boosting Consumption, Citing Finance Ministry

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB – Research Report) and Traws Pharma (...

Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and Traws Pharma (TRAW)

Traws Pharma GAAP EPS of -$8.81, revenue of $0.06M in-line

Onconova Therapeutics Inc ( ($TRAW) ) has released its Q3 earnings. Here is a breakdown of the information Onconova Therapeutics Inc presented to i...

Traws Pharma Reports Promising Antiviral Drug Progress

Traws Pharma, Inc. (TRAW) has disclosed a new risk, in the Corporate Activity and Growth category. The integration of Onconova and Trawsfynydd pose...

Traws Pharma Faces Uncertain Future Amid Complex Onconova Merger

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Traws Pharma (TRAW – Research Report), with a price targ...

Noble Financial Sticks to Their Buy Rating for Traws Pharma (TRAW)

Which subsectors to own and which to avoid – Wolfe Research

Traws Pharma (TRAW) announced progress in the development of its investigational one-dose influenza investigational therapy, tivoxavir marboxil for...

Traws Pharma announces progress in the development of tivoxavir marboxil

09:44 EST Traws Pharma (TRAW) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Traws Pharma Inc trading resumes

09:39 EST Traws Pharma (TRAW) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-mo...

Traws Pharma Inc trading halted, volatility trading pause

Traws stock rockets 260% on bird flu drug update

AAPL

AMZN

BIIB

BILI

BRCC

CRDO

DBAW

DFAX

ESPO

FTXG

GLBE

GOOGL

IBUY

KBWB

MAGS

MATV

MSFT

NLSP

ONLN

PRFX

QUAL

REPYY

RGTI

SCHG

SDVY

SMOT

SOCL

SOXX

SPYG

SPYV

SUPV

TRAW

TROX

TZOO

WEST

Press Releases

General

Traws Pharma's ICAR Poster Highlights Potency of COVID-19 Candidate

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Earnings

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Health Care

Management

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Comments

Traws Pharma

Traws Pharma (TRAW) 옵션

Traws Pharma (NASDAQ:TRAW) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌